Tarsus Pharmaceuticals, Inc.
TARS
$69.20
$0.320.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 69.41% | 106.87% | 128.39% | 146.68% | 151.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 69.41% | 106.87% | 128.39% | 146.68% | 151.54% |
| Cost of Revenue | 94.21% | 61.81% | 32.86% | 60.01% | -59.30% |
| Gross Profit | 67.80% | 121.93% | 175.07% | 187.36% | 278.28% |
| SG&A Expenses | 46.29% | 60.51% | 89.31% | 87.59% | 75.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.25% | 60.76% | 75.76% | 81.80% | 68.45% |
| Operating Income | 10.26% | 76.70% | 67.34% | 42.26% | 33.39% |
| Income Before Tax | 22.15% | 81.63% | 72.68% | 46.26% | 38.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.80% | 72.27% | 63.77% | 46.26% | 38.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.80% | 72.27% | 63.77% | 46.26% | 38.90% |
| EBIT | 10.26% | 76.70% | 67.34% | 42.26% | 33.39% |
| EBITDA | 12.99% | 77.98% | 68.60% | 43.45% | 34.27% |
| EPS Basic | 10.97% | 74.59% | 67.35% | 51.59% | 45.44% |
| Normalized Basic EPS | 10.50% | 81.07% | 91.99% | 51.60% | 42.07% |
| EPS Diluted | 10.97% | 74.59% | 67.35% | 51.59% | 45.44% |
| Normalized Diluted EPS | 10.50% | 81.07% | 91.99% | 51.60% | 42.07% |
| Average Basic Shares Outstanding | 2.44% | 9.18% | 10.95% | 11.01% | 12.00% |
| Average Diluted Shares Outstanding | 2.44% | 9.18% | 10.95% | 11.01% | 12.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |